Claudia Wild
Overview
Explore the profile of Claudia Wild including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
789
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goetz G, Schandelmaier S, Busse R, Wild C, Panteli D
Int J Technol Assess Health Care
. 2025 Feb;
41(1):e9.
PMID: 39909858
Objectives: The EUnetHTA Core Model is well-established in the HTA community. Some recommendations of corresponding guidance documents leave room for alternative methodological choices. Considering the new HTA regulation (HTAR), we...
2.
Schmidt L, Sehic O, Theuretzbacher U, Fabian D, Wild C
J Pharm Policy Pract
. 2025 Jan;
18(1):2449045.
PMID: 39845745
Background: Within the context of increasing transparency around public contributions, a framework for reporting and analysing public contributions to research and development (R&D) was previously developed and is piloted here...
3.
Wild C, Sehic O, Schmidt L, Fabian D
Health Policy
. 2024 Dec;
152:105235.
PMID: 39675231
Background And Objective: Article 57 of the proposed European Union (EU) Pharmaceutical Legislation (PL, Directive) will require market authorization applicants to publicly declare any direct financial support for R&D received...
4.
Zechmeister-Koss I, Gotz G, Fabian D, Wild C
Int J Technol Assess Health Care
. 2024 Nov;
40(1):e51.
PMID: 39498481
In many countries, the economics domain forms a routine part of health technology assessments (HTA) next to analyzing the comparative effectiveness and safety of a technology. The method applied most...
5.
Stemer G, Mittermayr T, Schnell-Inderst P, Wild C
Eur J Hosp Pharm
. 2024 Aug;
PMID: 39209448
The objectives were to summarise the evidence and clinical experts' views comparing the use of decentralised produced chimeric antigen receptor (CAR) T-cell therapies versus commercially available products, regarding drug costs,...
6.
Giess D, Erdos J, Wild C
Eur J Paediatr Neurol
. 2024 Jun;
51:84-92.
PMID: 38905882
Objective: This systematic review provides an update on outcomes for patients with spinal muscular atrophy (SMA) type 1 to 4 treated with approved therapeutics, including the most recent, risdiplam, for...
7.
Grossmann-Waniek N, Riegelnegg M, Gassner L, Wild C
Surg Endosc
. 2024 Feb;
38(3):1139-1150.
PMID: 38307958
Background: In surgical advancements, robot-assisted surgery (RAS) holds several promises like shorter hospital stays, reduced complications, and improved technical capabilities over standard care. Despite extensive evidence, the actual patient benefits...
8.
Wild C, Gotz G, Wernly B
Int J Cardiol Heart Vasc
. 2023 Dec;
49:101299.
PMID: 38059169
No abstract available.
9.
Mapping horizon scanning systems for medical devices: similarities, differences, and lessons learned
Ormstad S, Wild C, Erdos J, Moulton K
Int J Technol Assess Health Care
. 2023 Nov;
39(1):e69.
PMID: 37933611
Objectives: This article presents the mapping of horizons scanning systems (HSS) for medical devices, conducted by the Medical Devices Working Group of the International Horizon Scanning Initiative (IHSI MDWG). It...
10.
Goetz G, Jeindl R, Panteli D, Busse R, Wild C
Health Policy Technol
. 2023 Sep;
12(3):None.
PMID: 37732005
Purpose: To elaborate a concept for implementing digital health applications (DiHA), including prioritisation criteria (PC) for the Austrian context and an overview of available prioritised DiHAs. Methods: Based on European...